Market Intelligence, Clinical Progress, and High-Purity Reagents for Inflammatory, Fibrotic, and Oncology Disease Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for LIGHT/CD258/TNFSF14 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | LIGHT/CD258/TNFSF14 ECD-Fc / Trimeric Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 expressed. |
View LIGHT Products |
| Gene Delivery | LIGHT/CD258/TNFSF14 Promise-ORF / Lentivirus Full-length ORF for stable cell line generation. |
View LIGHT Products |
| Benchmark Ab | Anti-LIGHT/CD258 (Sequence of Millicibart / AVTX-002) Recombinant positive control antibody. |
View LIGHT Products |
| Validator | LIGHT/CD258/TNFSF14 siRNA Set For knockdown verification in functional assays. |
View LIGHT Products |
| Related Target A | HVEM/TNFRSF14 Primary signaling receptor mediating T-cell activation and inflammatory pathways. |
View HVEM Products |
| Related Target B | LTβR/Lymphotoxin-beta Receptor Dual receptor for LIGHT; critical for tissue remodeling, stromal cell activation, and fibrosis. |
View LTbetaR Products |
| Related Target C | DcR3/TNFRSF6B Soluble decoy receptor regulating LIGHT bioactivity; essential for counter-screening. |
View DcR3 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Multi-receptor cross-reactivity profiling (HVEM vs. LTβR) | Human, Mouse, and Cynomolgus ortholog proteins available with >95% purity and sequence verification. |
| Decoy receptor (DcR3) interference screening | Recombinant DcR3 decoy proteins strictly verified by mass spectrometry for competitive binding assays. |
| Lack of standardized clinical benchmarks | Sequence-verified Clinical Benchmark Antibodies (Biosimilars) available as positive controls. |
| Non-specific binding in complex matrices | Endotoxin-controlled, mammalian-expressed (HEK293) proteins preserving native glycosylation patterns. |
Live LIGHT/CD258/TNFSF14 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic targeting of the LIGHT/CD258/TNFSF14 axis is undergoing a significant expansion, transitioning from its historical focus on oncology immunostimulation to a highly prioritized pathway in severe inflammatory and fibrotic diseases. As a prominent TNF superfamily member, LIGHT mediates its biological activities through two functional receptors—HVEM (expressed on T-cells) and LTβR (expressed on epithelial/stromal cells)—while being regulated by the soluble decoy receptor DcR3.
The race for LIGHT-targeted therapeutics is intensifying, with major players shifting focus from traditional oncology mAbs to highly selective blocking antibodies for autoimmune indications such as severe asthma, inflammatory bowel disease (IBD), and Crohn's disease. As first-generation therapies reach late-stage clinical trials, the next wave of R&D is targeting multi-specific biologics and precision screening to bypass decoy receptor interference and optimize tissue-specific receptor blockade.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibodies (Blocking) | Avalo Therapeutics, Amgen, Sanofi | Severe Asthma, Crohn's Disease, COVID-19 ARDS | Receptor blocking assays (Need high-purity, trimeric LIGHT and receptor proteins) |
| Bispecific / Multi-specifics | Roche, AstraZeneca | Inflammatory Bowel Disease (IBD), Fibrosis | Dual-targeting validation (Need cross-species reactive HVEM and LTβR proteins) |
| Oncolytic/mRNA Delivery (Agonistic) | OncoSec, Moderna | Solid Tumors (Immuno-oncology) | Expression validation & signaling assays (Need Lentivirus-mediated stable cell lines) |